These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35577228)

  • 1. Understanding racial disparities in prurigo nodularis.
    Sutaria N; Semenov YR; Kwatra SG
    J Am Acad Dermatol; 2022 Sep; 87(3):e111-e112. PubMed ID: 35577228
    [No Abstract]   [Full Text] [Related]  

  • 2. Racial disparities in mortality among patients with prurigo nodularis: A multi-center cohort study.
    Sutaria N; Adawi W; Brown I; Parthasarathy V; Roh YS; Choi J; Bordeaux ZA; Trinh P; Le TK; Deng J; Semenov YR; Kwatra SG
    J Am Acad Dermatol; 2022 Feb; 86(2):487-490. PubMed ID: 34560195
    [No Abstract]   [Full Text] [Related]  

  • 3. Epidemiology of Prurigo Nodularis compared with Psoriasis in Germany: A Claims Database Analysis.
    Ständer S; Ketz M; Kossack N; Akumo D; Pignot M; Gabriel S; Chavda R
    Acta Derm Venereol; 2020 Nov; 100(18):adv00309. PubMed ID: 33021323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Itch on Sleep Disturbance in Patients with Prurigo Nodularis.
    Gwillim EC; Nattkemper L; Yosipovitch G
    Acta Derm Venereol; 2021 Mar; 101(3):adv00424. PubMed ID: 33704503
    [No Abstract]   [Full Text] [Related]  

  • 5. Prurigo nodularis: New treatments on the horizon.
    Yosipovitch G
    J Am Acad Dermatol; 2020 Apr; 82(4):1035-1036. PubMed ID: 32172924
    [No Abstract]   [Full Text] [Related]  

  • 6. Prevalence of tuberculosis in patients with prurigo nodularis: A multicenter cross-sectional study.
    Cornman HL; Kambala A; Chen S; Zhang J; Reddy SV; Kwatra SG
    J Am Acad Dermatol; 2023 Aug; 89(2):406-408. PubMed ID: 37062464
    [No Abstract]   [Full Text] [Related]  

  • 7. Dermal Periostin: A New Player in Itch of Prurigo Nodularis.
    Hashimoto T; Nattkemper LA; Kim HS; Kursewicz CD; Fowler E; Shah SM; Nanda S; Fayne RA; Romanelli P; Yosipovitch G
    Acta Derm Venereol; 2021 Jan; 101(1):adv00375. PubMed ID: 33236123
    [No Abstract]   [Full Text] [Related]  

  • 8. Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis.
    Serra-Baldrich E; Santamaría-Babí LF; Francisco Silvestre J
    Actas Dermosifiliogr; 2022; 113(7):674-684. PubMed ID: 35842249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response.
    Husein-ElAhmed H; Steinhoff M
    J Dermatolog Treat; 2022 May; 33(3):1547-1553. PubMed ID: 33200955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Trial of treatment of pruritus in chronic nodular circumscribed lichenification (horny obtusus lichen or nodular prurigo of M. Hyde)].
    KARATCHENTZEFF
    Ann Dermatol Syphiligr (Paris); 1946; 6(5-6):278. PubMed ID: 20292542
    [No Abstract]   [Full Text] [Related]  

  • 11. [Neurohistological studies on the differential diagnosis of prurigo nodularis Hyde and of other forms of circumscribed lichenification].
    THIES W
    Arch Klin Exp Dermatol; 1955; 201(6):539-55. PubMed ID: 13303208
    [No Abstract]   [Full Text] [Related]  

  • 12. Tralokinumab shows clinical improvement in patients with prurigo nodularis-like phenotype atopic dermatitis: A multicenter, prospective, open-label case series study.
    Pezzolo E; Gambardella A; Guanti M; Bianchelli T; Bertoldi A; Giacchetti A; Donini M; Argenziano G; Naldi L
    J Am Acad Dermatol; 2023 Aug; 89(2):430-432. PubMed ID: 37150301
    [No Abstract]   [Full Text] [Related]  

  • 13. Analysis of 325 Patients with Chronic Nodular Prurigo: Clinics, Burden of Disease and Course of Treatment.
    Gründel S; Pereira MP; Storck M; Osada N; Schneider G; Ständer S; Zeidler C
    Acta Derm Venereol; 2020 Sep; 100(16):adv00269. PubMed ID: 32556359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world disease burden and comorbidities of pediatric prurigo nodularis.
    Huang AH; Roh YS; Sutaria N; Choi J; Williams KA; Pritchard T; Alphonse MP; Canner JK; Grossberg AL; Kwatra SG
    J Am Acad Dermatol; 2022 Mar; 86(3):655-657. PubMed ID: 33600911
    [No Abstract]   [Full Text] [Related]  

  • 15. Prurigo nodularis: a benign dermatosis derived from a persistent pruritus.
    Vaidya DC; Schwartz RA
    Acta Dermatovenerol Croat; 2008; 16(1):38-44. PubMed ID: 18358109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis.
    Ständer S; Yosipovitch G; Legat FJ; Lacour JP; Paul C; Narbutt J; Bieber T; Misery L; Wollenberg A; Reich A; Ahmad F; Piketty C
    N Engl J Med; 2020 Feb; 382(8):706-716. PubMed ID: 32074418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline eosinophil level may be a predictive indicator for the effectiveness of dupilumab in patients with prurigo nodularis: A single-center, real-world prospective study.
    Yi X; Cao Q; Peng C; Jia Q; Li J
    J Am Acad Dermatol; 2024 May; 90(5):1076-1078. PubMed ID: 38296194
    [No Abstract]   [Full Text] [Related]  

  • 18. REMOVED: Plasma Steroids and Endocannabinoids Used as Biomarkers to Assess the Pruritus Severity of Patients With Prurigo Nodularis.
    Chu L; Wang LK; Wu Y; Yang H; Wang W; Lu Q; Deng H
    Actas Dermosifiliogr; 2022 Mar; 113(3):244-253. PubMed ID: 35282859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Our experience with prurigo nodularis treated with dupilumab.
    Tilotta G; Pistone G; Caruso P; Gurreri R; Castelli E; Curiale S; Caputo V; Bongiorno MR
    J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):e285-e287. PubMed ID: 33232536
    [No Abstract]   [Full Text] [Related]  

  • 20. Failure of Dupilimab With Severe Prurigo Nodularis That Responded Well to Abrocitinib.
    Vander Does A; Yosipovitch G
    Dermatitis; 2023; 34(6):567. PubMed ID: 36847309
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.